EP Wealth Advisors LLC Invests $641,000 in Cognex Corporation $CGNX

EP Wealth Advisors LLC purchased a new stake in shares of Cognex Corporation (NASDAQ:CGNXFree Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,855 shares of the scientific and technical instruments company’s stock, valued at approximately $641,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Cognex during the second quarter valued at $26,000. Geneos Wealth Management Inc. lifted its stake in shares of Cognex by 402.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company’s stock valued at $27,000 after purchasing an additional 736 shares during the period. Rakuten Securities Inc. acquired a new position in shares of Cognex in the 2nd quarter valued at $32,000. Elevation Wealth Partners LLC boosted its position in shares of Cognex by 635.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 478 shares of the scientific and technical instruments company’s stock worth $35,000 after purchasing an additional 413 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its position in shares of Cognex by 74.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 764 shares of the scientific and technical instruments company’s stock worth $35,000 after purchasing an additional 327 shares during the last quarter. Institutional investors and hedge funds own 88.12% of the company’s stock.

Cognex Trading Down 3.3%

Shares of Cognex stock opened at $58.54 on Tuesday. The company has a market capitalization of $9.85 billion, a PE ratio of 56.84 and a beta of 1.49. Cognex Corporation has a 12 month low of $34.60 and a 12 month high of $72.88. The stock’s fifty day simple moving average is $64.78 and its 200 day simple moving average is $59.01.

Cognex (NASDAQ:CGNXGet Free Report) last posted its earnings results on Wednesday, August 5th. The scientific and technical instruments company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.03. Cognex had a return on equity of 13.50% and a net margin of 16.05%.The firm had revenue of $291.26 million for the quarter, compared to analyst estimates of $292.10 million. During the same period in the previous year, the company posted $0.25 earnings per share. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. Cognex has set its FY 2026 guidance at 1.640-1.680 EPS and its Q3 2026 guidance at 0.500-0.540 EPS. Analysts predict that Cognex Corporation will post 1.68 EPS for the current fiscal year.

Cognex Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Thursday, August 20th. Cognex’s payout ratio is 33.01%.

Insider Buying and Selling at Cognex

In related news, VP Darren Marc Long sold 20,252 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $66.34, for a total value of $1,343,517.68. Following the completion of the transaction, the vice president directly owned 3,990 shares in the company, valued at approximately $264,696.60. The trade was a 83.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

CGNX has been the subject of a number of recent analyst reports. Barclays reiterated an “overweight” rating and issued a $80.00 price objective (up from $75.00) on shares of Cognex in a report on Monday, August 10th. DA Davidson set a $65.00 target price on Cognex and gave the stock a “neutral” rating in a report on Monday, August 10th. UBS Group set a $75.00 target price on Cognex in a research report on Tuesday, May 26th. Seaport Research Partners set a $75.00 price target on Cognex in a research note on Tuesday, May 26th. Finally, Weiss Ratings upgraded shares of Cognex from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.64.

Read Our Latest Stock Analysis on Cognex

About Cognex

(Free Report)

Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.

The company’s product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.

Featured Stories

Want to see what other hedge funds are holding CGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cognex Corporation (NASDAQ:CGNXFree Report).

Institutional Ownership by Quarter for Cognex (NASDAQ:CGNX)

Receive News & Ratings for Cognex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognex and related companies with MarketBeat.com's FREE daily email newsletter.